Skip to main content
. 2017 Nov 22;22(11):2038. doi: 10.3390/molecules22112038

Table 1.

OAD9(34) and experimental results.

Trial No. A B C D MPS (nm) ± SD
(n = 3)
1 1(25) 1(5) 1 (500) 1(4) 425.8 ± 45.22
2 1(25) 2(15) 2(1000) 2(25) 404.4 ± 34.83
3 1(25) 3(25) 3(1500) 3(35) 775.8 ± 29.12
4 2(35) 1(5) 2(1000) 3(35) 1129.2 ± 95.25
5 2(35) 2(15) 3(1500) 1(4) 368.4 ± 31.23
6 2(35) 3(25) 1(500) 2(25) 817.6 ± 70.69
7 3(45) 1(5) 3(1500) 2(25) 880.9 ± 50.18
8 3(45) 2(15) 1(500) 3(35) 1073.6 ± 88.90
9 3(45) 3(25) 2(1000) 1(4) 459.0 ± 28.92
K1 (a) 535.33 ± 36.39 901.967 ± 65.81 772.333 ± 68.27 417.733 ± 35.12
K2 861.73 ± 67.98 615.467 ± 51.65 754.2 ± 55.26 700.967 ± 51.90
K3 804.50 ± 56.00 684.133 ± 42.91 675.033 ± 36.84 1082.867 ± 73.35
R (b) 326.40 286.50 97.30 665.13
Optimal level A1 B2 C2 D1

A: concentration of vitexin solution (mg/mL); B: antisolvent to solvent volume ratio; C: stirring speed (rpm); D: reaction temperature. (a) KiA = Σ (mean particle size at Ai)/3, the mean values of the mean particle size for a certain factor at each level with standard deviation. (b) RiA = max{KiA} − min{KiA}.